SCHEMBL25546335

SCHEMBL25546335

CC(C)Cc1sc(Cl)nc1-c1cccs1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 4/20 0.50
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
ALDH1A1 P00352 7/20 0.40
KMT2A Q03164 5/20 0.40
MEN1 O00255 4/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
PSMD14 O00487 1/20 0.40
POLB P06746 1/20 0.40
RECQL P46063 1/20 0.40
KDM4E B2RXH2 4/20 0.38
HTT P42858 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
CACNA1B Q00975 1/20 0.38
APBA1 Q02410 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25558476 0.83 FBP1 (0.48) FBP1ADORA2AADORA1ALDH1A1KMT2A
SCHEMBL25546343 0.80 FBP1 (0.50) FBP1ALDH1A1MAPTKDM4ENPC1
SCHEMBL25546341 0.77 FBP1 (0.47) FBP1ALDH1A1MAPTLMNAHTT
SCHEMBL25546337 0.75 FBP1 (0.48) FBP1MAPT
SCHEMBL18282312 0.72 FBP1 (0.48) FBP1ALDH1A1MAPTLMNAL3MBTL1
SCHEMBL25546361 0.72 FBP1 (0.43) FBP1KMT2AMEN1MAPTLMNA
SCHEMBL25546346 0.71 FBP1 (0.48) FBP1MAPTLMNAPOLBNPC1
SCHEMBL25546334 0.71 FBP1 (0.44) FBP1ALDH1A1MAPT
SCHEMBL10130643 0.69 LTA4H (0.61) FBP1ALDH1A1KMT2AMEN1MAPT
SCHEMBL25546002 0.69 FBP1 (0.48) FBP1LMNAPOLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-05-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150997-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 FBP1 735/4885ADORA2A 4148/4885ADORA1 4694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.